Tafamidis Meglumine
Overview
Tafamidis Meglumine is a chaperone amyloid fibril inhibitor used for the treatment of patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and transthyretin-related hereditary amyloid polyneuropathy (hATTR-PN). It stabilizes transthyretin, thus preventing the misfolding and deposition of amyloid fibrils in tissues.
API suppliers (12)
Suppliers of Tafamidis Meglumine evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
Country recorded for 9 of 12 suppliers.
6 of 12 hold a GMP certificate on record in the EU or UK registers
- MSN Laboratories Private LimitedIndia1 active DMF GMP on record
- STHREE CHEMICALS LLCIndia1 active DMF
- Neuland Laboratories LimitedIndia1 active DMF
- ALIVUS LIFE SCIENCES LTDIndia1 active DMF GMP on record
- OPTIMUS DRUGS PRIVATE LTDIndia1 active DMF
- APITORIA PHARMA PRIVATE LTDIndia1 active DMF GMP on record
- HONOUR LAB LTDIndia1 active DMF GMP on record
- SAPTAGIR LABORATORIES PRIVATE LTDIndia1 active DMF
- NAVINTA LLCUnited States1 active DMF
- AURORE LIFE SCIENCES PRIVATE LTD1 active DMF GMP on record
- BIOPHORE INDIA PHARMACEUTICALS PVT LTD1 active DMF
- DR REDDYS LABORATORIES LTD1 active DMF GMP on record
Therapeutic areas
Do you supply Tafamidis Meglumine? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.